Hip Prospective Study

Sponsor
Societe dEtude, de Recherche et de Fabrication (Industry)
Overall Status
Recruiting
CT.gov ID
NCT05956236
Collaborator
(none)
5,000
1
275.3
18.2

Study Details

Study Description

Brief Summary

In an evaluation report dated 2014, the HAS (Haute Autorité de Santé -French National Authority for Health) highlights that long-term clinical data on hip prostheses are needed in the context of the French healthcare system. In addition, per the European Regulation 2017/745, medical devices manufacturers shall conduct Post-Market Clinical Follow-up (PMCF) on their devices or provide a justification why PMCF is not applicable.

Therefore, as part of the PMCF process of their hip prostheses, SERF wants to conduct a PMCF investigation to ensure the long-term real-life performance, safety and benefits of these prostheses.

HiPS is a non-comparative, prospective, multicentric, national, 15-year follow-up clinical investigation.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    5000 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Hip Prospective Study: Long-term Post-market Clinical Follow-up on the Use of SERF Hip Prostheses
    Actual Study Start Date :
    Apr 24, 2023
    Anticipated Primary Completion Date :
    Apr 1, 2046
    Anticipated Study Completion Date :
    Apr 1, 2046

    Outcome Measures

    Primary Outcome Measures

    1. Survival rate [Per operative period to 15 years]

      To assess the survival rate of the investigational medical devices at the end of their claimed implantation duration

    Secondary Outcome Measures

    1. Intermediate survival rates [Per operative period to 10 years]

      To assess the survival rate of the investigational medical devices at the intermediate timepoints

    2. Functional improvement [Per operative period to 15 years]

      To assess the evolution of patient's functional capacity post-implantation using HOOS score

    3. Functional improvement [Per operative period to 15 years]

      To assess the evolution of patient's functional capacity post-implantation using Harris Hips score

    4. Functional improvement [Per operative period to 15 years]

      To assess the evolution of patient's activity post-implantation using UCLA scale

    5. Functional improvement [Per operative period to 15 years]

      To assess the evolution of patient's activity post-implantation using Charnley score

    6. Leg length discrepancy [Pre operative period to 15 years]

      To assess patient's leg length discrepancy post-implantation (visual evaluation)

    7. Patient's Pain [Pre operative period to 15 years]

      To assess patient's pain (Visual Analogic Scale)

    8. Patient's quality of life [Pre operative period to 15 years]

      To assess patient's quality of life post-implantation (Forgotten Joint Score)

    9. Patient's satisfaction [Post operative period to 15 years]

      To assess patients' satisfaction with the operation (4-points question)

    10. Surgeon's satisfaction [Per operative period to 15 years]

      To assess surgeons' satisfaction with the operation

    11. Adverse events [Per operative period to 15 years]

      To assess the long-term safety of investigational medical devices as well as post-operative safety of the surgery

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Male or female adults

    • Planned to be implanted with investigational medical devices per the IFUs:

    • Implantation in skeletally mature adults (usually aged 60-65 and over), with an extremely painful and/or disabled joint and insufficiently improved by alternative treatment options after an observation period lasting from a few weeks to a few months

    • Implantation of investigational medical devices as integrated systems (all components from SERF, no component from another manufacturer)

    • For an intended purpose and indication listed in the IFUs

    • Affiliated to French social security

    • Who provided a dated and signed informed consent form

    Exclusion Criteria:
    • Patient protected by a French legal measure

    • Patient not able to express his/her consent as deemed by the investigator

    • Patient deprived of liberty or hospitalized without consent

    • Pregnant or breastfeeding women

    • Patient contraindicated to investigational medical devices implantation per the IFUs

    • Patient contraindicated to radiographic follow-up

    • Patient a priori not able to meet the follow-up visits as deemed by the investigator

    • Patient not able to fulfil a self-assessment questionnaire as deemed by the investigator.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 CHU St Etienne Saint-Priest-en-Jarez France 42270

    Sponsors and Collaborators

    • Societe dEtude, de Recherche et de Fabrication

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Societe dEtude, de Recherche et de Fabrication
    ClinicalTrials.gov Identifier:
    NCT05956236
    Other Study ID Numbers:
    • HiPS
    First Posted:
    Jul 21, 2023
    Last Update Posted:
    Jul 21, 2023
    Last Verified:
    May 1, 2023
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Societe dEtude, de Recherche et de Fabrication
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jul 21, 2023